12.1 Parenteral Nutrition: Solution Composition
Key Takeaways
- Parenteral nutrition (PN) supplies intravenous macronutrients and micronutrients when the GI tract cannot be used safely or adequately—classic indications include non-functioning gut, severe malabsorption, and prolonged NPO when enteral feeding is not feasible.
- Central PN uses a central venous access device for high-osmolarity, high-dextrose formulas; peripheral PN (PPN) is limited by osmolarity (teaching principle often <900 mOsm/L) and is not a substitute for full central PN when concentrated dextrose is required.
- Formulations are 2-in-1 (amino acids + dextrose, lipids separate) or 3-in-1 total nutrient admixture (TNA) with lipid injectable emulsion mixed in; components also include electrolytes, vitamins, trace elements, and sometimes insulin.
- Filter by formulation: 0.22-micron filter for lipid-free 2-in-1; 1.2-micron filter for 3-in-1 or any lipid-containing infusion—never use a 0.22 filter with lipids.
- Prefer a dedicated lumen, avoid piggybacking incompatible meds into PN, manage continuous vs cyclic schedules, advance rates carefully, respect hang times (often 24 hours for compounded PN), and watch calcium–phosphate compatibility and light-protection requirements.
Parenteral nutrition on the CRNI blueprint
Domain 3H Parenteral Nutrition expects infusion nurses to understand what PN is made of, where it can safely run, and how to administer it without creating infectious, metabolic, or mechanical disasters. This section focuses on solution composition, access route, filters, and administration. Section 12.2 covers infectious, metabolic, and mechanical complications plus monitoring.
Quick Answer: PN = IV nutrition when the gut cannot meet needs (non-functioning GI tract, severe malabsorption, prolonged NPO without adequate enteral options). High-osmolarity / high-dextrose formulas need central access; PPN is osmolarity-limited (often taught as <900 mOsm/L). Know 2-in-1 vs 3-in-1 (TNA), components, 0.22 vs 1.2 micron filters, dedicated lumen, no incompatible piggybacks, rate/hang-time rules, and Ca–PO₄ stability risks.
Indications: when PN is the right tool
Parenteral nutrition delivers amino acids, carbohydrate (as dextrose), lipid emulsion when ordered, electrolytes, vitamins, and trace elements intravenously. It is not first-line nutrition for every hospitalized patient who is NPO overnight. Prefer enteral nutrition whenever the gut works—enteral support preserves gut integrity and generally carries a better infection risk profile than long-term central PN.
Exam-level indications cluster around inability to use the GI tract adequately:
| Indication theme | Clinical examples (conceptual) |
|---|---|
| Non-functioning GI tract | Prolonged ileus, high-output fistula, severe obstruction not yet relieved, extensive bowel rest needs |
| Severe malabsorption | Short-bowel syndromes, severe mucosal disease when oral/enteral intake cannot meet goals |
| Prolonged NPO / inadequate intake | Extended NPO with anticipated inability to meet nutrition enterally within a clinically appropriate window |
| Other complex failure | When multidisciplinary nutrition teams determine IV support is required after enteral attempts fail or are contraindicated |
Exam trap: Ordering or expecting full PN solely because the patient “looks thin” or missed a few meals—indication requires a GI or intake barrier, not cosmetic underfeeding alone. Conversely, delaying needed PN when the gut is unusable for a prolonged period is also unsafe; CRNI tests clinical judgment themes, not inventing facility-specific day-count cutoffs.
Central PN vs peripheral PN (PPN)
Why osmolarity and dextrose drive the route
PN solutions are often hyperosmolar. Peripheral veins cannot safely tolerate highly concentrated dextrose and high total osmolarity for prolonged therapy—risk includes chemical phlebitis, pain, and infiltration with tissue injury. Central venous access (tip in the superior vena cava/cavoatrial region per confirmation standards) provides high blood flow for rapid dilution of concentrated formulas.
| Feature | Central PN | Peripheral PN (PPN) |
|---|---|---|
| Access | CVAD (PICC, nontunneled CVC, tunneled catheter, port—as ordered and appropriate) | Short peripheral or other peripheral-compatible access meeting policy |
| Osmolarity | High osmolarity acceptable with central dilution | Teaching principle: often limit ~<900 mOsm/L for peripheral administration |
| Dextrose concentration | Higher dextrose concentrations typical for full calorie goals | Lower dextrose / more dilute formulas; high dextrose needs central access |
| Role | Standard route for complete, longer-term PN | Temporary, limited nutritional support when central access is not yet available or full PN is not indicated |
| Exam trap | Using a peripheral IV for a high-dextrose central PN bag | Assuming PPN can always replace central PN calorie-for-calorie |
Key principle: If the ordered formula’s dextrose concentration and total osmolarity require central administration, do not “make do” with a peripheral IV because a central line is inconvenient. If only PPN is available, the formula itself must be designed for peripheral limits—pharmacy and the nutrition support team own compounding limits; nursing owns route verification against the order and product labeling.
Access device considerations for PN
- Prefer a dedicated lumen for PN when a multi-lumen CVAD is used—reduces contamination and incompatible medication mixing at the hub.
- Confirm tip position before initiating central PN per institutional imaging/ECG confirmation policy.
- Midlines and short PIVs are not interchangeable with central lines for hyperosmolar central PN—device class must match formula risk.
- Assess the entire delivery path: pump, filter, set integrity, and securement so the line does not interrupt nutrition for preventable mechanical reasons.
Formulation types: 2-in-1 vs 3-in-1 (TNA)
Macronutrient building blocks
| Component | Role |
|---|---|
| Amino acids | Protein source for synthesis and repair |
| Dextrose | Primary carbohydrate calorie source; major driver of osmolarity and hyperglycemia risk |
| Lipid injectable emulsion (ILE) | Calorie-dense fat source; prevents essential fatty acid deficiency (EFAD) when lipids are omitted long-term; affects filter choice and hang rules |
| Electrolytes | Sodium, potassium, magnesium, calcium, phosphate, acetate/chloride balance as ordered |
| Vitamins | Multivitamin packages; some are light-sensitive |
| Trace elements | Zinc, copper, selenium, chromium, manganese (and others as formulated)—doses individualized by team |
| Insulin (sometimes) | May be added for glycemic control in selected protocols—high-alert medication handling applies |
2-in-1 vs 3-in-1
| Formulation | Contents | Clinical notes |
|---|---|---|
| 2-in-1 | Amino acids + dextrose (+ additives) in one bag; lipids infused separately (or omitted) | Clearer visual inspection of the AA/dextrose bag; lipid line/filter managed independently |
| 3-in-1 / TNA (total nutrient admixture) | Amino acids + dextrose + lipid emulsion in one container | Opaque/milky appearance can hide precipitates; special stability and filter rules apply |
Visual inspection matters: look for cracks, leaks, discoloration, and (in lipid-containing products) signs of cracking or phase separation (oil layering) that make the emulsion unsafe. When in doubt, do not hang—call pharmacy.
Filters: a high-yield CRNI trap
In-line filtration is part of PN safety culture. Match pore size to lipid content:
| Situation | Filter teaching principle |
|---|---|
| 2-in-1 without lipids (amino acid/dextrose only) | 0.22-micron filter commonly taught for bacterial retention on lipid-free PN |
| 3-in-1 / TNA or any lipid-containing infusion | 1.2-micron filter—lipids require the larger pore; do not use 0.22 with lipids |
| Separate lipid piggyback | Follow product and facility filter guidance consistent with lipid emulsion requirements (1.2-micron class thinking) |
Exam trap #1: Selecting a 0.22-micron filter for a milky 3-in-1 bag “because tighter is safer.” Lipids will clog or be retained improperly; use the 1.2-micron approach taught for lipid-containing PN.
Exam trap #2: Omitting the filter entirely because “the bag is already sterile.” Filters are a prescribed safety step for particulate and (where indicated) microbial risk reduction—follow order set and standards of practice.
Place filters per manufacturer and facility policy (commonly close to the patient on the administration set), prime carefully to avoid air, and replace with set changes per hang-time policy.
Administration principles
Dedicated lumen and medication compatibility
PN is chemically complex. Do not piggyback incompatible medications into a running PN line. Many drugs precipitate with electrolytes, change pH, or destabilize lipid emulsions. Safe patterns:
- Prefer a dedicated PN lumen.
- If multi-lumen access exists, reserve one lumen for PN and use others for medications when ordered.
- When only one lumen exists, consult pharmacy for Y-site compatibility data—never assume saline compatibility equals PN compatibility.
- Never use the PN bag as a convenient “carrier fluid” for random IV pushes.
Continuous vs cyclic PN
| Mode | Pattern | Why used |
|---|---|---|
| Continuous | Runs over ~24 hours | Common in acute initiation and unstable patients; steady dextrose delivery |
| Cyclic | Infused over a shorter daily window (e.g., overnight), off part of the day | Home PN lifestyle, hepatobiliary rest concepts in long-term therapy, mobility during the day |
Cycling requires planned taper up/down of rates so blood glucose does not swing wildly. Abruptly stopping high-dextrose PN without a taper or replacement dextrose plan risks rebound hypoglycemia (covered in depth in 12.2).
Start and advance rates
Initiation is typically start low, advance as tolerated, especially in patients at risk for refeeding syndrome. Exact calorie and electrolyte advance schedules are ordered by the nutrition support team/prescriber. Nursing responsibilities:
- Program smart pumps accurately; use drug/library entries when available for PN.
- Monitor glucose and electrolytes during advancement.
- Do not unilaterally “catch up” large volumes of missed PN by doubling rates without an order—metabolic risk is real.
- Coordinate bag changes to minimize prolonged interruptions of dextrose in insulin-treated or high-dextrose regimens.
Hang time
Teaching principles commonly tested:
- Compounded PN hang time is often 24 hours (facility policy may refine start time from spike vs compound time).
- Lipid hang rules may differ when lipids run separately—know that lipid emulsions have specific maximum hang durations and must not sit room-temperature indefinitely after opening/spiking.
- Change administration sets with the bag per policy; do not extend sets beyond infection-control limits because “there’s still fluid left.”
Compatibility, stability, and light protection
Calcium–phosphate precipitation
Calcium and phosphate can form insoluble precipitates in PN, especially with high concentrations, unfavorable pH, elevated temperature, and certain admixture sequences. Precipitates may be occult in lipid-containing TNAs (milky color masks crystals). Embolization of precipitate is a never-event risk theme.
Nursing actions:
- Inspect lipid-free bags against light for haze or crystals before hanging.
- For TNA, trust pharmacy compounding controls, still inspect for emulsion breakdown, and use correct filters.
- Do not add calcium or phosphate at the bedside to a hanging bag.
- Stop the infusion and escalate if in-line filter occlusion, unexplained respiratory distress, or visible precipitate appears.
Light protection and other stability notes
Some PN components (certain vitamins, specific additives) are light-sensitive. When pharmacy labels protect from light, use light-protective covers and do not leave bags in direct sunlight under a window for hours. Temperature excursions (extreme heat/freezing) can also ruin emulsions and vitamin stability—store and transport per label.
Putting composition knowledge into practice
Scenario A — Route mismatch: An order for high-dextrose central PN arrives with only a peripheral IV in place. Correct action: do not start the central formula peripherally; obtain appropriate central access (or a pharmacy-revised PPN formula if clinically intended) and verify tip position before initiation.
Scenario B — Filter choice: A 3-in-1 TNA is ready to hang. Select a 1.2-micron filter pathway—not 0.22.
Scenario C — Shared lumen temptation: A nurse wants to piggyback a vancomycin dose into the only lumen running PN “because the other lines are clogged.” Correct thinking: stop and solve access/compatibility properly with pharmacy and the team—do not improvise incompatible Y-sites into PN.
High-yield exam traps (composition & administration)
- Using a peripheral IV for high-dextrose / high-osmolarity central PN
- Using a 0.22-micron filter with lipids / 3-in-1
- Treating PPN as equivalent full replacement for central PN calorie goals
- Piggybacking incompatible meds into the PN lumen
- Ignoring dedicated lumen preference on multi-lumen CVADs
- Adding electrolytes or insulin to the bag outside pharmacy control
- Extending hang time past policy because the bag is “not empty”
- Missing Ca–PO₄ precipitation risk and failing to inspect / escalate
- Omitting light protection when labeled
- Confusing 2-in-1 (lipids separate) with 3-in-1 TNA filter and inspection rules
A patient is ordered high-dextrose central parenteral nutrition, but only a short peripheral IV is currently available. What is the safest nursing action?
Which filter selection matches standard teaching for parenteral nutrition formulations?
What is the main clinical distinction between a 2-in-1 PN formulation and a 3-in-1 total nutrient admixture (TNA)?
Which practice best reflects safe PN administration regarding vascular access and medications?